博瑞医药：拟发行H股股票并在香港联合交易所主板上市

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its international strategy and enhance overseas business development, aiming to improve its capital strength and overall competitiveness [1] Group 1 - The company will hold the 12th meeting of the 4th Board of Directors and the 10th meeting of the 4th Supervisory Board on September 26, 2025 [1] - The proposals under review include the issuance of H-shares and the plan for listing on the main board of the Hong Kong Stock Exchange [1] - The company intends to consider the interests of existing shareholders and market conditions when determining the timing for the issuance and listing [1]